Drug intelligence / Profile preview

LY3200882 + capecitabine

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Oral

Overview

LY3200882 + capecitabine is an investigational combination therapy being evaluated for the treatment of advanced, chemotherapy-resistant colorectal cancer (CRC) in patients with an activated TGF-beta signature. This combination is specifically studied within Stratum 3 of the MoTriColor platform trial, led by the Netherlands Cancer Institute. LY3200882 is a small molecule inhibitor of the Transforming Growth Factor-beta (TGF-beta) receptor type I (ALK5), designed to block TGF-beta signaling, which often promotes tumor progression and immune evasion in CRC. Capecitabine is an oral fluoropyrimidine carbamate that functions as a prodrug of 5-fluorouracil (5-FU), an antimetabolite that inhibits thymidylate synthase and interferes with DNA synthesis. The rationale for the combination is to utilize TGF-beta inhibition to overcome resistance mechanisms and enhance the efficacy of cytotoxic chemotherapy in molecularly selected patients.

Brand names: Xeloda
Other names: LY3200882 and capecitabineLY-3200882 and capecitabineLY 3200882 and capecitabine

Targets

TGFBR1TS (Thymidylate synthase)

Beyond the preview

Go deeper on LY3200882 + capecitabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY3200882 + capecitabine.

Explore the full profile